Jairo A Fonseca1, Jessica N McCaffery2, Juan Caceres2, Elena Kashentseva3, Balwan Singh2, Igor P Dmitriev3, David T Curiel3, Alberto Moreno4. 1. Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, United States; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30307, United States. 2. Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, United States. 3. Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine 660 S. Euclid Ave., 4511 Forest Park Blvd, St. Louis, MO 63108, United States. 4. Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, United States; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30307, United States. Electronic address: alberto.moreno@emory.edu.
Abstract
INTRODUCTION: Cellular and humoral immune responses are both involved in protection against Plasmodium infections. The only malaria vaccine available, RTS,S, primarily induces short-lived antibodies and targets only a pre-erythrocytic stage antigen. Inclusion of erythrocytic stage targets and enhancing cellular immunogenicity are likely necessary for developing an effective second-generation malaria vaccine. Adenovirus vectors have been used to improve the immunogenicity of protein-based vaccines. However, the clinical assessment of adenoviral-vectored malaria vaccines candidates has shown the induction of robust Plasmodium-specific CD8+ but not CD4+ T cells. Signal peptides (SP) have been used to enhance the immunogenicity of DNA vaccines, but have not been tested in viral vector vaccine platforms. OBJECTIVES: The objective of this study was to determine if the addition of the SP derived from the murine IgGκ light chain within a recombinant adenovirus vector encoding a multistage P. vivax vaccine candidate could improve the CD4+ T cell response. METHODS: In this proof-of-concept study, we immunized CB6F1/J mice with either the recombinant simian adenovirus 36 vector containing the SP (SP-SAd36) upstream from a transgene encoding a chimeric P. vivax multistage protein or the same SAd36 vector without the SP. Mice were subsequently boosted twice with the corresponding recombinant proteins emulsified in Montanide ISA 51 VG. Immunogenicity was assessed by measurement of antibody quantity and quality, and cytokine production by T cells after the final immunization. RESULTS: The SP-SAd36 immunization regimen induced significantly higher antibody avidity against the chimeric P. vivax proteins tested and higher frequencies of IFN-γ and IL-2 CD4+ and CD8+ secreting T cells, when compared to the unmodified SAd36 vector. CONCLUSIONS: The addition of the murine IgGκ signal peptide significantly enhances the immunogenicity of a SAd36 vectored P. vivax multi-stage vaccine candidate in mice. The potential of this approach to improve upon existing viral vector vaccine platforms warrants further investigation.
INTRODUCTION: Cellular and humoral immune responses are both involved in protection against Plasmodium infections. The only malaria vaccine available, RTS,S, primarily induces short-lived antibodies and targets only a pre-erythrocytic stage antigen. Inclusion of erythrocytic stage targets and enhancing cellular immunogenicity are likely necessary for developing an effective second-generation malaria vaccine. Adenovirus vectors have been used to improve the immunogenicity of protein-based vaccines. However, the clinical assessment of adenoviral-vectored malaria vaccines candidates has shown the induction of robust Plasmodium-specific CD8+ but not CD4+ T cells. Signal peptides (SP) have been used to enhance the immunogenicity of DNA vaccines, but have not been tested in viral vector vaccine platforms. OBJECTIVES: The objective of this study was to determine if the addition of the SP derived from the murine IgGκ light chain within a recombinant adenovirus vector encoding a multistage P. vivax vaccine candidate could improve the CD4+ T cell response. METHODS: In this proof-of-concept study, we immunized CB6F1/J mice with either the recombinant simian adenovirus 36 vector containing the SP (SP-SAd36) upstream from a transgene encoding a chimeric P. vivax multistage protein or the same SAd36 vector without the SP. Mice were subsequently boosted twice with the corresponding recombinant proteins emulsified in Montanide ISA 51 VG. Immunogenicity was assessed by measurement of antibody quantity and quality, and cytokine production by T cells after the final immunization. RESULTS: The SP-SAd36 immunization regimen induced significantly higher antibody avidity against the chimeric P. vivax proteins tested and higher frequencies of IFN-γ and IL-2CD4+ and CD8+ secreting T cells, when compared to the unmodified SAd36 vector. CONCLUSIONS: The addition of the murine IgGκ signal peptide significantly enhances the immunogenicity of a SAd36 vectored P. vivax multi-stage vaccine candidate in mice. The potential of this approach to improve upon existing viral vector vaccine platforms warrants further investigation.
Authors: Arturo Reyes-Sandoval; Tamara Berthoud; Nicola Alder; Loredana Siani; Sarah C Gilbert; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Adrian V S Hill Journal: Infect Immun Date: 2009-10-26 Impact factor: 3.441
Authors: Alison E Mahan; Madeleine F Jennewein; Todd Suscovich; Kendall Dionne; Jacquelynne Tedesco; Amy W Chung; Hendrik Streeck; Maria Pau; Hanneke Schuitemaker; Don Francis; Patricia Fast; Dagna Laufer; Bruce D Walker; Lindsey Baden; Dan H Barouch; Galit Alter Journal: PLoS Pathog Date: 2016-03-16 Impact factor: 6.823
Authors: Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Eleanor M Riley; Kent E Kester; Christian F Ockenhouse; Azra C Ghani Journal: PLoS One Date: 2013-04-16 Impact factor: 3.240
Authors: Yuanyuan Li; Darren B Leneghan; Kazutoyo Miura; Daria Nikolaeva; Iona J Brian; Matthew D J Dicks; Alex J Fyfe; Sarah E Zakutansky; Simone de Cassan; Carole A Long; Simon J Draper; Adrian V S Hill; Fergal Hill; Sumi Biswas Journal: Sci Rep Date: 2016-01-08 Impact factor: 4.379
Authors: Hüseyin Can; Ahmet Efe Köseoğlu; Sedef Erkunt Alak; Mervenur Güvendi; Mert Döşkaya; Muhammet Karakavuk; Adnan Yüksel Gürüz; Cemal Ün Journal: Sci Rep Date: 2020-12-28 Impact factor: 4.379